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Key Clinical Message
Survival of stage 4 ganglioneuroblastoma (GNB) patients is poor; no reports
exist of patients surviving up to 5 years (1, 2). We report the clinical and thera-
peutic course of a patient with stage 4 GNB surviving beyond expectations due
to a multimodal treatment approach incorporating new technologies in cancer
diagnostic and treatment.
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Case
In November 2009, a previously healthy 34-year-old man
presented with abdominal pain.
A CT scan showed a 4- 9 7-cm tumor located in the
retroperitoneum. Preoperative blood samples and bone
marrow aspirates were normal.
Surgery was performed; the tumor was growing into
the wall of vena cava and could not be radically resected.
The histopathological report described a solid tumor,
8 9 5 cm, with encapsulated proliferation of atypical
ganglion cells interspersed between a fibrillary matrix.
The cells were immunoreactive for synaptophysin, chro-
mogranin A, FLI-1, and CD56. Fifteen percent of the cells
were proliferating according to KI67. No amplification of
myc-n, 22q12, 1p, or 17q was found. The findings were
consistent with a ganglioneuroblastoma but with some
cells more resembling neuroblastoma.
Postoperative 18-fluorodeoxyglucose positron emission
tomography/computed tomography (FDG-PET/CT) showed
persisting tumor in the tumor bed and a small malignant
process with high FDG uptake located in the spine at the
12th thoracic vertebra.
From January 2010 to June 2010, the patients under-
went chemotherapy with cyclophosphamide, vincristine,
and doxorubicin, alternating with carboplatin and etopo-
side. After four series, radiotherapy consisting of 60 Gy in
30 fractions was delivered to the tumor bed and to the
spinal tumor.
In October 2011, recurrence consisting of four localized
bone metastases to the pelvis and spine was detected on
FDG-PET/CT. The patient was treated with another four
series of chemotherapy consisting of cyclophosphamide,
vincristine, and doxorubicin, alternating with carboplatin
and etoposide. Additionally, radiation therapy with 54 Gy
in 18 fractions was delivered to the bone metastases.
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Additional fluorescence in situ hybridization analysis
(FISH) of the initial tumor specimen revealed an activat-
ing anaplastic lymphoma kinase (ALK) mutation F1174L
in all tumor cells.
In November 2012, the patient developed progressive
bone metastases and he started treatment with the ALK
inhibitor crizotinib. In January 2014, FDG-PET/CT
showed complete remission of all lesions.
In July 2014, the bone metastases in the spine pro-
gressed again. 68Ga-DOTATOC PET/CT showed grade 4
uptake in the metastases; the patient stopped treatment
with crizotinib and was referred to peptide receptor
radionuclide therapy (PRRT) with 177Lu-DOTATATE
given four times in intervals of 2 months.
In June 2015, 68Ga-DOTATOC PET/CT revealed new
bone lesions.
The original tumor specimen underwent further analy-
sis for mutations in 50 genes using next-generation
sequencing (NGS) with Ion AmpliSeq Cancer Hotspot
Panel v2 and AmpliSeq Colon Lung Cancer Hotspot
Panel v2.
The NGS analysis revealed an activating epidermal
growth factor receptor (EGFR)-mutation L861Q in the
tumor cells resembling neuroblastoma; the patient started
treatment with the EGFR inhibitor erlotinib.
In January 2016, FDG-PET/CT showed multiple new
bone metastases; the patient started treatment with the
second-generation ALK inhibitor ceritinib.
As of April 2016, the patient is still in an excellent clin-
ical condition, working full time as a high school teacher
and responding to treatment.
Discussion
This case describes the clinical and therapeutic course of
an adult patient with stage IV GNB who is still alive
7 years after diagnosis and who continues to respond to
treatment. Previously, no patients with stage IV GNB
have been reported to live beyond 5 years after diagnosis
[3, 4].
The negative prognostic factors in GNB are age at diag-
nosis (children <1 year old have a more favorable prog-
nosis), advanced stage, primary tumor located in the
retroperitoneum or in the adrenal glands, and tumor pre-
senting with amplification of N-MYC and deletion of the
short arm of chromosome 1 [5, 6].
The presented patient had all these prognostic factors
except for amplification of N-MYC and deletion of the
short arm of chromosome.
Traditionally, treatment strategies incorporate surgery,
radiotherapy, and chemotherapy based upon guidelines
derived from pediatric experience.
In pediatric populations, patients have responded to
first-line chemotherapy with cyclophosphamide, vin-
cristine and doxorubicin, and combinations with plat-
inum and etoposide [7]. For relapsed disease, topotecan
and temozolomide have shown effect [8, 9]. Over the
last decade, tyrosine kinase inhibitors (TKIs) have been
developed to target specific pathways associated with
tumor growth. In lung cancer patients, inhibition of the
EGFR and inhibition of the echinoderm microtubule-
associated protein-like 4 ALK fusion oncogene are well-
known therapies for patients with specific mutations in
these genes [10]. The effect of TKIs in metastatic GNB is
not clear.
In neuroblastomas, EGFR mutations have been
reported very rare, and ALK mutations have been
reported to occur in 8% of tumors [11, 12].
In general, detection of gene mutations and identifica-
tion of patient subgroups that will benefit from a particu-
lar drug have improved with the use of NGS analysis
[13].
The tumor specimen of the presented patient had an
ALK mutation (F1174L) in all the tumor cells examined
by FISH analysis; using NGS analysis, an additional
EGFR-mutation (L861Q) was found in the less differenti-
ated part of the tumor resembling neuroblastoma. Both
mutations were successfully targeted with TKIs resulting
in clinical response.
In neuroendocrine tumors (NETs), somatostatin recep-
tors are also used for targeted therapy in PRRT and for
imaging. In imaging, the ability to tag somatostatin ana-
logs with 68Ga has revolutionized the role of PET in diag-
nosis, staging, and therapy monitoring of patients with
receptor-positive NETs.
In PRRT, somatostatin receptors are targeted with radio-
labeled peptides, thereby delivering a high radiation dose
specifically to the tumor. The amount of tumor somato-
statin receptors correlates with the efficacy of PRRT. In
patients with a grade 3 or 4 uptake of somatostatin analogs,
PRRT with any of the known radiolabeled somatostatin
analogs such as 111In-DTPA octreotide, 90Y-DOTATOC, or
177Lu-DOTATATE can result in symptomatic improve-
ment [14].
Adverse effects of PRRT are few and mostly mild [15].
Serious, delayed adverse effects such as myelodysplastic
syndrome, renal failure, or leukemia are rare. However,
loss of kidney function can occur after PRRT, with a
decrease in creatinine clearance of about 4% per year for
177Lu-DOTATATE [16].
Our patient was treated four times with 177Lu-DOTA-
TATE during 8 months; he has had no decrease in kidney
function or bone marrow toxicity, and the bone metas-
tases were stabilized.
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In conclusion, this case underscores the importance of
adapting a multimodal, therapeutic approach in patients
with rare tumors such as GNB. By incorporating new
technologies into cancer diagnostic and treatment,
patients with otherwise limited therapy options could be
offered treatment resulting in a possible improvement in
survival rates. The potential adverse effects of increasing
treatment intensity are a concern. In this case, however,
side-effects were limited; the patient is working full time
as a high school teacher, is responding to treatment, and
is alive 7 years after being diagnosed with stage IV GNB.
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